Naa10p Enhances Chemosensitivity to Cisplatin in Oral Squamous Cell Carcinoma Cells

References

• Brocklehurst PR, Baker SR. Speight PM Oral cancer screening: what have we learnt and what is there still to achieve? Future Oncol. 2010;6:299–304. doi:10.2217/fon.09.16320146588
   PubMed Web of Science ®Google Scholar
• Kessler P, Grabenbauer G, Leher A, et al. Neoadjuvant and adjuvant therapy in patients with oral squamous cell carcinoma Long-term survival in a prospective, non-randomized study. Br J Oral Maxillofac Surg. 2008;46:1–5. doi:10.1016/j.bjoms.2007.08.00617931758
   PubMed Web of Science ®Google Scholar
• Furness S, Glenny AM, Worthington HV, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev. 2010;4:CD006386.
   Google Scholar
• Daniela DSS, Michael H, Alex M, et al. Recurrent oral cancer: current and emerging therapeutic approaches. Front Pharmacol. 2012;3:149.23060791
   PubMed Web of Science ®Google Scholar
• Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3:1351–1371. doi:10.3390/cancers301135124212665
   PubMedGoogle Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–1883. doi:10.1038/onc.2011.38421892204
   PubMed Web of Science ®Google Scholar
• Xu H, Jiang B, Meng L, et al. N-α-acetyltransferase 10 protein inhibits apoptosis through RelA/p65-regulated MCL1 expression. Carcinogenesis. 2012;33:1193–1202. doi:10.1093/carcin/bgs14422496479
   PubMed Web of Science ®Google Scholar
• Zeng Y, Zheng J, Zhao J, et al. High expression of Naa10p associates with lymph node metastasis and predicts favorable prognosis of oral squamous cell carcinoma. Tumour Biol. 2016;37:6719–6728. doi:10.1007/s13277-015-4563-z26662107
   PubMedGoogle Scholar
• Zeng Y, Min L, Han Y, et al. Inhibition of STAT5a by Naa10p contributes to decreased breast cancer metastasis. Carcinogenesis. 2014;35:2244–2253. doi:10.1093/carcin/bgu13224925029
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhou H, Tao Y, et al. ARD1 contributes to IKKβ-mediated breast cancer tumorigenesis. Cell Death Dis. 2018;9:860. doi:10.1038/s41419-018-0921-230154412
   PubMed Web of Science ®Google Scholar
• Lee EJ, Seo JH, Park JH, et al. SAMHD1 acetylation enhances its deoxynucleotide triphosphohydrolase activity and promotes cancer cell proliferation. Oncotarget. 2017;8:68517–68529. doi:10.18632/oncotarget.1970428978134
   PubMedGoogle Scholar
• Lee D, Jang MK, Seo JH, et al. ARD1/NAA10 in hepatocellular carcinoma: pathways and clinical implications. Exp Mol Med. 2018;50:1–12. doi:10.1038/s12276-018-0187-x
   Web of Science ®Google Scholar
• Hua KT, Tan CT, Johansson G, et al. N-α-acetyltransferase 10 protein suppresses cancer cell metastasis by binding PIX proteins and inhibiting Cdc42/Rac1 activity. Cancer Cell. 2011;19:218–231. doi:10.1016/j.ccr.2010.11.01021295525
   PubMed Web of Science ®Google Scholar
• Kuhns KJ, Zhang G, Wang Z, et al. ARD1/NAA10 acetylation in prostate cancer. Exp Mol Med. 2018;50:1–8. doi:10.1038/s12276-018-0107-0
   PubMed Web of Science ®Google Scholar
• Yang H, Li Q, Niu J, et al. microRNA-342-5p and miR-608 inhibit colon cancer tumorigenesis by targeting NAA10. Oncotarget. 2016;7:2709–2720. doi:10.18632/oncotarget.645826646451
   PubMedGoogle Scholar
• Jiang B, Ren T, Dong B, et al. Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am J Pathol. 2010;177:1095–1103. doi:10.2353/ajpath.2010.09117820639454
   PubMed Web of Science ®Google Scholar
• Arnesen T, Gromyko D, Pendino F, et al. Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex. Oncogene. 2006;25:4350–4360. doi:10.1038/sj.onc.120946916518407
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216. doi:10.1093/jnci/92.3.20510655437
   PubMed Web of Science ®Google Scholar
• Wernyj RP, Morin PJ. Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel. Drug Resist Updat. 2004;7:227–232. doi:10.1016/j.drup.2004.08.00215533760
   PubMed Web of Science ®Google Scholar
• Kalvik TV. Arnesen T Protein N-terminal acetyltransferases in cancer. Oncogene. 2013;32:269–276. doi:10.1038/onc.2012.8222391571
   PubMed Web of Science ®Google Scholar
• Kuo HP, Lee DF, Chen CT, et al. ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci Signal. 2010;3:ra9. doi:10.1126/scisignal.200059020145209
   PubMed Web of Science ®Google Scholar
• Zheng J, Sun L, Yuan W, et al. Clinical value of Naa10p and CEA levels in saliva and serum for diagnosis of oral squamous cell carcinoma. J Oral Pathol Med. 2018;47:830–835. doi:10.1111/jop.1276730028540
   PubMed Web of Science ®Google Scholar
• Fisher TS, Etages SD, Hayes L, et al. Analysis of ARD1 function in hypoxia response using retroviral RNA interference. J Biol Chem. 2005;280:17749–17757. doi:10.1074/jbc.M41205520015755738
   PubMed Web of Science ®Google Scholar
• Nagelkerke A, Mujcic H, Bussink J, et al. Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer. Cancer. 2011;117:3670–3681. doi:10.1002/cncr.2593821319150
   PubMed Web of Science ®Google Scholar
• Brabec V, Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat. 2002;5:147–161. doi:10.1016/S1368-7646(02)00047-X12237082
   PubMed Web of Science ®Google Scholar
• Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8:59950–59964.28938696
   PubMed Web of Science ®Google Scholar
• Hatok J, Racay P. Bcl-2 family proteins: master regulators of cell survival. Biomol Concepts. 2016;7:259–270.27505095
   PubMedGoogle Scholar
• Lu D, Shi HC, Wang ZX, et al. Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma. Br J Biomed Sci. 2011;68:69–74. doi:10.1080/09674845.2011.1173032621706917
   PubMed Web of Science ®Google Scholar
• van Eerd JE, de Geus-oei LF, Oyen WJ, et al. Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody. Eur J Nucl Med Mol Imaging. 2006;33:1266–1272. doi:10.1007/s00259-006-0152-016832635
   PubMed Web of Science ®Google Scholar
• Park J, Kanayama A, Yamamoto K, et al. ARD1 binding to RIP1 mediates doxorubicin-induced NF-κB activation. Biochem Biophys Res Commun. 2012;422:291–297. doi:10.1016/j.bbrc.2012.04.15022580278
   PubMed Web of Science ®Google Scholar
• Suenaga N, Kuramitsu M, Komure K, et al. Loss of tumor suppressor CYLD expression triggers cisplatin resistance in oral squamous cell carcinoma. Int J Mol Sci. 2019;20:5194. doi:10.3390/ijms20205194
   PubMed Web of Science ®Google Scholar